AKBA — Akebia Therapeutics Balance Sheet
0.000.00%
- $594.64m
- $581.46m
- $160.18m
- 30
- 30
- 84
- 46
Annual balance sheet for Akebia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K/A | 10-Q | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 269 | 150 | 90.5 | 42.9 | 51.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 26.9 | 51.6 | 40.3 | 39.3 | 34.4 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 371 | 271 | 185 | 118 | 114 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 35.5 | 40.6 | 34.4 | 16 | 10.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 644 | 529 | 356 | 242 | 221 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 187 | 261 | 130 | 99.9 | 80.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 397 | 455 | 351 | 272 | 270 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 248 | 74 | 5.23 | -30.6 | -49.2 |
Total Liabilities & Shareholders' Equity | 644 | 529 | 356 | 242 | 221 |
Total Common Shares Outstanding |